Clinical Trials
158 trialsNCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT02649855 2026-04-29
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03218826 2026-04-29
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT01446731 2024-07-03
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Herlev Hospital
Phase 2 Completed
NCT02453009 2024-05-30
CHEIRON
Santa Chiara Hospital
Phase 2 Completed
NCT03358563 2024-05-03
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Completed
NCT03311555 2024-03-19
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Duke University
Phase 2 Completed
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00482807 2023-11-24
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Phase 1 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00258388 2023-08-04
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT00471432 2023-08-04
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01619813 2023-08-04
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00027859 2023-06-15
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02740985 2023-05-26
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT02598895 2022-11-17
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
Phase 2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05471427 2022-07-22
ANCHISES
Azienda Ospedaliero-Universitaria Careggi
Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00589420 2022-02-17
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02376296 2022-02-17
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
Saladax Biomedical, Inc.
Completed
NCT03101046 2022-02-10
TACTIK
UNICANCER
Phase 2 Completed
NCT00116142 2022-01-11
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT01254513 2021-06-10
GERICO10
UNICANCER
Phase 2 Completed
NCT00916123 2021-05-20
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Completed
NCT00087165 2021-04-28
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT00104715 2021-02-21
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
UNICANCER
Phase 3 Completed
NCT01882985 2021-01-05
Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
University of California, Irvine
Phase 2 Completed
NCT00411528 2020-12-17
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT01160705 2020-11-17
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
Cancer Trials Ireland
Completed
NCT02036060 2020-11-16
ABIDO
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT00466440 2020-11-06
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
Eli Lilly and Company
Phase 2 Completed
NCT00030654 2020-10-22
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed